Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of Asporin as a HER3 ligand that exposes a therapeutic vulnerability in metastatic prostate cancer [ASPN_MyCCaP_10111-AH]

ABSTRACT: Identification of Asporin as a HER3 ligand that exposes a therapeutic vulnerability in metastatic prostate cancer [ASPN_MyCCaP_10111-AH]

PROVIDER: PRJNA1133008 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR29737991_1.fastq.gz	Fastqsanger.gz
	SRR29737991_2.fastq.gz	Fastqsanger.gz
	SRR29737992_1.fastq.gz	Fastqsanger.gz
	SRR29737992_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 7

Similar Datasets

Identification of Asporin as a HER3 ligand that exposes a therapeutic vulnerability in metastatic prostate cancer [ASPN_MyCCaP_10111-AH]

Project description:Cancer-associated fibroblasts (CAF) are part of the tumor microenvironment that enable cancer cells to establish metastases, but the mechanisms of these interactions are not fully known. Herein, we identify a novel paracrine mechanism in which CAF-secreted asporin (ASPN) activates ErbB signaling and subsequent migration of adjacent metastatic prostate cancer cells. Our data support that ASPN binds directly to HER3 to induce HER2/HER3 heterodimerization and activation of the PI3-kinase and MAP-kinase pathways. Genetic and therapeutic inhibition of HER2/HER3 ablated ASPN-induced signaling and migration. Small molecule and antibody-drug conjugates targeting HER2/HER3 demonstrated efficacy in vitro, with near complete resolution of tumors in vivo. Clinically, over 50% of human prostate cancer metastases show expression of HER2/HER3, along with ASPN expressing CAF. Collectively, these findings support ASPN functions as a HER3 ligand to induce cellular migration which can be targeted with anti-HER2/HER3 therapies, highlighting the potential clinical benefit for patients with metastatic prostate cancer.

2025-06-25 | GSE271738 | GEO

Identification of Asporin as a HER3 ligand that exposes a therapeutic vulnerability in metastatic prostate cancer [NRG1_MyCCaP_10722-AH]

2025-06-25 | GSE271740 | GEO

Identification of Asporin as a HER3 ligand that exposes a therapeutic vulnerability in metastatic prostate cancer [NRG1_MyCCaP_10722-AH]

Project description:Identification of Asporin as a HER3 ligand that exposes a therapeutic vulnerability in metastatic prostate cancer [NRG1_MyCCaP_10722-AH]

| PRJNA1133009 | ENA

Identification of Asporin as a HER3 ligand that exposes a therapeutic vulnerability in metastatic prostate cancer

2025-06-25 | GSE284054 | GEO

Identification of Asporin as a HER3 ligand that exposes a therapeutic vulnerability in metastatic prostate cancer (NRG1)

2025-06-25 | GSE271580 | GEO

Identification of Asporin as a HER3 ligand that exposes a therapeutic vulnerability in metastatic prostate cancer (ASPN)

2025-06-25 | GSE271579 | GEO

Identification of Asporin as a HER3 ligand that exposes a therapeutic vulnerability in metastatic prostate cancer [LNCaP_EnzaResistant_9445-HYW]

2025-06-25 | GSE271739 | GEO

Identification of Asporin as a HER3 ligand that exposes a therapeutic vulnerability in metastatic prostate cancer [VCaP_EnzaResistant_9817-HYW]

2025-06-25 | GSE271742 | GEO

Identification of Asporin as a HER3 ligand that exposes a therapeutic vulnerability in metastatic prostate cancer